Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;27(5):923-931.
doi: 10.1007/s10787-019-00618-0. Epub 2019 Jul 16.

Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis

Nayana Venugopal #  1 , Pooja Acharya #  1 , Mehrdad Zarei  1 , Ramaprasad Ravichandra Talahalli  2
Affiliations

Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis

Nayana Venugopal et al. Inflammopharmacology. 2019 Oct.

Abstract

Background and aims: Though cyclooxygenase inhibitors are employed in rheumatoid arthritis treatment, modulators of leukotrienes are underexplored. We investigated the therapeutic potential of montelukast, a known cysteinyl leukotriene receptor-1 (CysLT1) inhibitor in an experimental rat model of arthritis.

Methods: Arthritis was induced in rats, and montelukast (5 mg/kg body wt.) was administered prophylactically (PAM) and therapeutically (TAM) through oral route.

Results and discussion: Blood and joint tissue markers of oxidative stress (lipid peroxidation, protein carbonyls, and nitric oxides) were significantly (p < 0.05) reduced in montelukast administered rats. Paw inflammation, RA markers (RF and CRP), eicosanoids (PGE2, LTB4, and LTC4), cytokines (IL-1β and MCP-1), activity of hydrolytic enzymes (collagenase, elastase, and hyaluronidase), expression of matrix metalloproteinases (MMP), and EP-4 receptor were significantly (p < 0.05) reduced in montelukast administered rats. This study established that leukotriene inhibition through montelukast lowered the severity of arthritis and thus a potential strategy for reducing the severity of arthritis.

Keywords: Cytokines; Eicosanoids; Inflammation; Montelukast; Rheumatoid arthritis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Abramson SB, Amin A (2002) Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology 41(9):972–980 - DOI
    1. Bieth J, Spiess B, Wermuth CG (1974) The synthesis and analytical use of a highly sensitive and convenient substrate of elastase. Biochem Med 11(4):350–357 - DOI
    1. Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM (2011) Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res 12(1):114 - DOI
    1. Bousquet J, Demoly P, Humbert M (2009) Montelukast in guidelines and beyond. Adv Ther 26(6):575–587 - DOI
    1. Brand D, Latham KA, Rosloniec EF (2007) Collagen-induced arthritis. Nat Protoc 2(5):1269–1275 - DOI